Spyre Therapeutics (SYRE) EBT (2016 - 2025)
Historic EBT for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to -$11.2 million.
- Spyre Therapeutics' EBT rose 8379.51% to -$11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.0 million, marking a year-over-year increase of 3065.78%. This contributed to the annual value of -$208.0 million for FY2024, which is 3861.95% up from last year.
- According to the latest figures from Q3 2025, Spyre Therapeutics' EBT is -$11.2 million, which was up 8379.51% from -$36.7 million recorded in Q2 2025.
- In the past 5 years, Spyre Therapeutics' EBT ranged from a high of -$6.7 million in Q2 2021 and a low of -$217.1 million during Q2 2023
- Over the past 5 years, Spyre Therapeutics' median EBT value was -$24.4 million (recorded in 2022), while the average stood at -$41.5 million.
- In the last 5 years, Spyre Therapeutics' EBT tumbled by 87281.53% in 2023 and then soared by 8379.51% in 2025.
- Over the past 5 years, Spyre Therapeutics' EBT (Quarter) stood at -$20.4 million in 2021, then rose by 8.03% to -$18.8 million in 2022, then tumbled by 236.35% to -$63.2 million in 2023, then increased by 10.9% to -$56.3 million in 2024, then skyrocketed by 80.14% to -$11.2 million in 2025.
- Its last three reported values are -$11.2 million in Q3 2025, -$36.7 million for Q2 2025, and -$44.8 million during Q1 2025.